Last reviewed · How we verify
allogenic natural killer cells
At a glance
| Generic name | allogenic natural killer cells |
|---|---|
| Also known as | OT-C001, NK-001 |
| Sponsor | Emercell SAS |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) (PHASE1, PHASE2)
- Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia (PHASE3)
- Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) (PHASE2)
- Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors (PHASE1)
- CIML NK Cells With Venetoclax for AML (PHASE1)
- Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma (PHASE1, PHASE2)
- Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) (PHASE1, PHASE2)
- Intraperitoneal SK-NK Cell Injection for Advanced Ovarian Cancer With Massive Ascites (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- allogenic natural killer cells CI brief — competitive landscape report
- allogenic natural killer cells updates RSS · CI watch RSS
- Emercell SAS portfolio CI